| Symbol | Company | Owner | Relationship | Date | Transaction | Cost | # Shares | Value ($) | Total Shares | Filing | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | MACKAY MARTIN | Director | May 13, 2024 | Option Exercise | $228.41 | 931 | 212,650 | 12,531 | May 15, 2024, 05:52 PM | |
| RLYB | Rallybio Corp | MACKAY MARTIN | Chief Executive Officer | Jan 10, 2022 | Buy | $10.10 | 5,504 | 55,590 | 278,113 | Jan 12, 2022, 06:56 PM | |
| RLYB | Rallybio Corp | MACKAY MARTIN | Chief Executive Officer | Jan 11, 2022 | Buy | $10.65 | 4,496 | 47,882 | 282,609 | Jan 12, 2022, 06:56 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 27, 2017 | Sale | $131.20 | 860 | 112,832 | 38,883 | Mar 01, 2017, 07:45 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 28, 2017 | Sale | $131.70 | 625 | 82,312 | 38,258 | Mar 01, 2017, 07:45 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Mar 01, 2017 | Sale | $132.50 | 370 | 49,025 | 50,688 | Mar 01, 2017, 07:45 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 09, 2017 | Sale | $126.84 | 217 | 27,524 | 39,743 | Feb 10, 2017, 06:05 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 06, 2017 | Sale | $125.70 | 2,728 | 342,904 | 39,978 | Feb 08, 2017, 04:39 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | May 16, 2016 | Sale | $139.20 | 4,097 | 570,284 | 42,706 | May 18, 2016, 04:36 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 29, 2016 | Sale | $138.91 | 1,000 | 138,910 | 46,785 | Mar 01, 2016, 06:34 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 05, 2016 | Sale | $141.75 | 2,105 | 298,377 | 44,756 | Feb 08, 2016, 07:56 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 08, 2016 | Sale | $138.09 | 1,966 | 271,481 | 42,693 | Feb 08, 2016, 07:56 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Aug 03, 2015 | Option Exercise | $130.29 | 43,500 | 5,667,488 | 76,393 | Aug 05, 2015, 06:09 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Aug 03, 2015 | Sale | $196.52 | 43,500 | 8,548,418 | 59,293 | Aug 05, 2015, 06:09 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | May 14, 2015 | Sale | $160.33 | 4,056 | 650,298 | 32,893 | May 22, 2015, 05:30 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Mar 02, 2015 | Sale | $180.34 | 370 | 66,726 | 36,949 | Mar 03, 2015, 09:13 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Feb 10, 2015 | Sale | $173.97 | 3,897 | 677,956 | 34,126 | Feb 12, 2015, 09:07 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Nov 03, 2014 | Option Exercise | $104.86 | 9,375 | 983,063 | 33,801 | Nov 04, 2014, 06:36 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Nov 03, 2014 | Sale | $191.52 | 9,375 | 1,795,500 | 24,426 | Nov 04, 2014, 06:36 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Jun 12, 2014 | Option Exercise | $104.86 | 25,000 | 2,621,500 | 49,426 | Jun 13, 2014, 05:31 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | Jun 12, 2014 | Sale | $166.42 | 25,000 | 4,160,565 | 44,368 | Jun 13, 2014, 05:31 PM | |
| ALXN | ALEXION PHARMACEUTICALS INC | MACKAY MARTIN | EVP & Global Head of R&D | May 14, 2014 | Sale | $160.85 | 3,574 | 574,878 | 24,426 | May 15, 2014, 05:11 PM |
Menu